These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9629645)

  • 1. Local influence in linear mixed models.
    Lesaffre E; Verbeke G
    Biometrics; 1998 Jun; 54(2):570-82. PubMed ID: 9629645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu; Rasner PI; Skobelev PP
    Urologiia; 2001; (6):48-54. PubMed ID: 11785083
    [No Abstract]   [Full Text] [Related]  

  • 4. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early detection of prostatic carcinoma: Is PSA screening suitable?].
    Kaulen H
    Dtsch Med Wochenschr; 2003 May; 128(18):977. PubMed ID: 12755136
    [No Abstract]   [Full Text] [Related]  

  • 6. PSA scores: should we use a lower threshold?
    Carter HB
    Johns Hopkins Med Lett Health After 50; 2004 Oct; 17(8):6. PubMed ID: 15602780
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
    Romppanen J; Haapalainen T; Punnonen K; Penttilä I
    Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making sense of PSA.
    Thompson IM
    Health News; 2001 Apr; 7(4):3. PubMed ID: 11303477
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
    Bratt O; Björk T
    Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
    [No Abstract]   [Full Text] [Related]  

  • 10. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
    Pauler DK; Finkelstein DM
    Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining longitudinal studies of PSA.
    Inoue LY; Etzioni R; Slate EH; Morrell C; Penson DF
    Biostatistics; 2004 Jul; 5(3):483-500. PubMed ID: 15208207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Usefulness of free prostate specific antigen in the detection of prostate cancer].
    Azócar G; Castillo O; Van Cauwelaert R; Cumsille MA; Campero JM; Aguirre C; Wöhler C
    Rev Med Chil; 1999 Feb; 127(2):151-7. PubMed ID: 10436694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the analysis of mixed longitudinal growth data.
    Huggins RM; Loesch DZ
    Biometrics; 1998 Jun; 54(2):583-95. PubMed ID: 9660630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic value of complexed prostate-specific antigen for prostate cancer].
    Su HW; Li Y; Xu P
    Zhonghua Nan Ke Xue; 2003 Sep; 9(6):431-3. PubMed ID: 14574807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer diagnosis: importance of individualized risk stratification models over PSA alone.
    Chun FK; Karakiewicz PI; Briganti A
    Eur Urol; 2008 Aug; 54(2):241-2. PubMed ID: 18538466
    [No Abstract]   [Full Text] [Related]  

  • 18. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ROC (receiver operating characteristics) curve: principles and application in biology].
    Delacour H; Servonnet A; Perrot A; Vigezzi JF; Ramirez JM
    Ann Biol Clin (Paris); 2005; 63(2):145-54. PubMed ID: 15771972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro PSA : a "pro cancer" form of PSA?
    Peyromaure M; Fulla Y; Debré B; Dinh-Xuan AT
    Med Hypotheses; 2005; 64(1):92-5. PubMed ID: 15533620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.